Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer
Status:
Not yet recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
Cadonilimab is a first-in-class bispecific, humanized IgG1 antibody targeting PD-1 and
CTLA-4, which has the potential to boost immune surveillance in tumors.
This was a phase II study of cadonilimab in combination with bevacizumab and FOLFOXIRI as
first line therapy for metastatic microsatellite stable (MSS) colorectal cancer. The goal of
this clinical trial is to evaluated the efficacy and safety.